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REVIEW
Biochemical functionality of magnetic 
particles as nanosensors: how far away are we 
to implement them into clinical practice?
Simon Doswald1, Wendelin Jan Stark1 and Beatrice Beck‑Schimmer2*
Abstract 
Magnetic nanosensors have become attractive instruments for the diagnosis and treatment of different diseases. They 
represent an efficient carrier system in drug delivery or in transporting contrast agents. For such purposes, magnetic 
nanosensors are used in vivo (intracorporeal application). To remove specific compounds from blood, magnetic 
nanosensors act as elimination system, which represents an extracorporeal approach. This review discusses principles, 
advantages and risks on recent advances in the field of magnetic nanosensors. First, synthesis methods for magnetic 
nanosensors and possibilities for enhancement of biocompatibility with different coating materials are addressed. 
Then, attention is devoted to clinical applications, in which nanosensors are or may be used as carrier‑ and elimination 
systems in the near future. Finally, risk considerations and possible effects of nanomaterials are discussed when work‑
ing towards clinical applications with magnetic nanosensors.
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Background
Functionalization of magnetic nanoparticles (MNPs) for 
biomedical and clinical applications as nanosensors has 
received considerable attention in the past. Particularly 
in cancer diagnosis and treatment, magnetic nanosensors 
are widely explored as potential alternatives, either to 
identify less invasive diagnostic tools such as collection 
of cancer cells or tissue material or to specifically deliver 
medications within the tumor.
A magnetic nanosensor is a MNP functionalized with 
sensing moieties, which interact with proteins, DNA or 
cell surfaces. While many magnetic nanosensors are 
available, this review will exclusively focus on magnetic 
nanosensors designed to be used as diagnostic or thera-
peutic tools in medicine. Magnetic nanoparticles for 
general biomedical applications [1–5], or distinctive 
applications [6–11] are described elsewhere.
From a clinical perspective, it is important to make 
a distinction between magnetic nanosensors applied 
in vivo (intracorporeal approach) and magnetic nanosen-
sors, which are used extracorporeally (extracorporeal 
approach). The distinction is important since different 
requirements for materials, properties and handling are 
needed. Concerning in  vivo applications, drugs are 
attached to MNPs and carried to a specific location, a 
process called drug delivery. In another in  vivo system, 
magnetic nanosensors as contrast agents are available 
to convert a biochemical information (e.g. tumor tissue) 
through radiation into an analytic signal (imaging of the 
tumor) in magnetic resonance imaging (MRI). In extra-
corporeal approaches such as blood purification, mag-
netic nanosensors are used to bind and collect specific 
biochemical or cellular entities that on the top allow for 
detailed analysis or diagnosis after recovery of the sen-
sors. Blood purification with magnetic nanosensors can 
be considered similar to a dialysis device, whereas no 
sensor particles are allowed to reach the body after the 
purified blood is redirected to the patient [12].
When aiming towards magnetic nanosensors in clinical 
applications the material and synthesis are key for their 
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functionality. Therefore, the following section will cover 
different synthesis pathways and functionalizations of 
MNPs. Subsequently, chances of applying nanosensors in 
different medical applications as well as risk considera-
tions when using nanomaterials are discussed.
Magnetic nanoparticles: material and synthesis
There are a number of ways to synthesize MNPs, which 
are described in detail by Schüth et  al. [13]. As a brief 
overview, several techniques are used: (i) Co-precipita-
tion, with which iron oxides are synthesized using aque-
ous salt solutions. Under inert atmosphere and through 
the addition of base, iron oxide is precipitated. (ii) Ther-
mal decomposition, where organometallic precursors 
in high boiling solvents are decomposed by heating to 
either metal or metal-oxide nanoparticles. With this 
method, depending on solvent and precursor, very small 
particles (1–20 nm) are synthesized. (iii) Microemulsion: 
two immiscible liquids including a surfactant are used to 
form micelles. Within the micelles, the desired precur-
sor is transformed to the corresponding nanoparticle. (iv) 
Hydrothermal synthesis: Li et al. [14] reported a liquid–
solid-solution phase transfer synthesis pathway preparing 
various metal nanoparticles. Another method for prepar-
ing MNPs hydrothermally is the so called hot-injection 
technique [15]. It is a widely used method for the prepa-
ration of monodisperse nanoparticles and quantum dots. 
This approach involves the injection of a room tem-
perature precursor solution, generally a metal-chloride 
or -methylate, into a hot high-boiling-point liquid. The 
high temperature hinders further nucleation. Therefore, 
it is possible to fabricate very size-uniform nanoparti-
cles. (v) Flame synthesis: This is a synthesis route, which 
was first used to prepare oxide and non-oxide ceramics 
such as silica and pigmentary titania [16], followed by the 
production of various other oxide nanoparticles in pilot 
scale quantities [17]. Subsequently, this method has been 
adapted to produce also non-noble metal nanoparticles 
[18]. Due to their air instability, attributed to the small 
size of these metallic MNPs, they oxidize spontaneously. 
Therefore, such MNPs are not usable as possible candi-
dates for magnetic nanosensors. By the addition of acet-
ylene and subsequently modifying the flame synthesis 
conditions, however, metallic MNPs are stabilized with 
a carbon layer as shown using cobalt particles [19]. Car-
bon-coated metallic MNPs are air-, solvent- and in a wide 
range pH-stable [20]. Another significant advantage of 
carbon layers is the possibility to perform chemical mod-
ification in order to covalently bind functional groups. As 
a consequence, in the meantime many differently func-
tionalized carbon-coated MNPs were designed [21–32].
With the described surface modification and function-
alization carbon-coated MNPs became as interesting 
as the already widely explored superparamagnetic iron 
oxide nanoparticles (SPIONs) [33]. SPIONs are generally 
composed of γ-Fe2O3 or  Fe3O4. In comparison to other 
metal and metal-oxide nanoparticles, SPIONs have the 
advantage of being compatible in a biological environ-
ment [34]. Also, they undergo biodegradation [34]. This 
has made SPIONs prominent candidates for in vivo appli-
cations. Biodegradation of SPIONs is dependent on coat-
ing and coating material as well as on size. Coating 
influences biodegradation due to partial hindered access 
to the metal-oxide core [35]. Concerning biodegradation, 
very small particles (< 20 nm) will be quickly eliminated 
in the body by the kidneys, whereas on the other hand 
large nanoparticles (> 200 nm) will be filtered in the liver 
and spleen [36]. These are important aspects when aim-
ing at an in vivo application of the nanoparticles.
The main difference between carbon-coated MNPs 
and SPIONs, from a pure materials point of view, is the 
higher saturation magnetization of the former, which 
leads to a much faster separation of carbon-coated MNPs 
when applying a magnetic field. Additionally, SPIONs are 
superparamagnetic while carbon-coated MNPs are fer-
romagnetic [37]. This means that carbon-coated MNPs 
have a tendency to aggregate due to their permanent 
magnetization, which may impose a challenge when 
using bare carbon-coated MNPs for in  vivo applica-
tions. However, aggregation may be hindered by surface 
modification of the carbon-coated MNPs to produce 
stable dispersions [38]. Furthermore, magnetic proper-
ties of nanoparticles can also be influenced by other fac-
tors than the material choice such as size of the particles, 
crystallinity, shape and composition [39]. This should be 
considered when tailoring nanoparticles towards specific 
properties and applications.
Physicochemical characteristics of the synthesized 
magnetic nanosensors determine biocompatibility. 
As a consequence, interactions with the biological 
milieu such as the blood have to be considered care-
fully. Blood is a complex liquid consisting of different 
molecular and cellular entities. Therefore, it is impor-
tant to ensure that magnetic nanosensors do not inter-
fere with blood in any other way than intended, nor 
should they induce any unwanted reactions such as 
inflammation. In general, a suitable coating with a pol-
ymer is sufficient to achieve biocompatibility before 
the sensing functionality is implemented (Fig.  1). A 
widely applied approach is dextran coating of nanosen-
sors used as contrast agents for MRI [40–42]. Another 
possibility to coat MNPs with a polymer is the use 
of atomic transfer radical polymerization (ATRP), a 
technique, which allows the production of a variety of 
polymers [43]. This approach is utilized to polymerize 
functionalized methacrylate onto carbon-coated cobalt 
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nanoparticles in order to achieve stable dispersions of 
MNPs [38]. These functionalized nanoparticles have 
an azide moiety, which may be further modified by 
“click”-reaction to include substrates that may be used 
for biomedical applications [38]. An additional bio-
compatible polymer is polyglycerol (PG). Polyglycerol 
has a chain structure similar to polyethylene glycol 
(PEG). The advantage of PG is its optimal hydrophilic-
ity, stability and resistance to non-specific adsorption 
of proteins [44]. A simple one-step synthetic approach 
for PG is anionic ring opening polymerization, which 
results in a hyperbranched polymer. Biocompatibil-
ity of such PG was tested. Results revealed similar or 
even better behaviour of PG compared to PEG [45, 46]. 
Recently, hyperbranched PG was polymerized onto 
MNPs  (Fe2O3). As a consequence, MNPs have become 
resistant to nonspecific adsorption of proteins [47]. 
Due to the simple synthesis process, the biocompat-
ibility as well as the possibility for further functionali-
zation, PG coating is a valuable alternative approach 
for the preparation of magnetic nanosensors for bio-
medical applications.
Opportunities using magnetic nanosensors
The use of magnetic nanosensors in clinical applications 
will be discussed based on the two categories of intracor-
poreal (in vivo) and extracorporeal applications. This will 
be covered in the sections Magnetic nanosensors as car-
rier system, focusing on in  vivo methods, and Magnetic 
nanosensors as elimination system for the extracorporeal 
removal of a molecular or cell entity from blood.
Magnetic nanosensors as carrier system
Drug delivery
Magnetic nanoparticles are considered ideal candidates 
for drug delivery for several reasons. Their large surface-
to volume ratio allows for a high loading with active 
substances. Moreover, these MNPs can be directed by a 
magnet and facilitate targeted delivery of drugs. Finally, 
stable dispersions and fast transportation in fluids can be 
realized due to the small size of the MNPs.
A subcategory for drug delivery is the group of chem-
otherapeutics. Classically, therapy with a chemothera-
peutic drug is non-specific and the drug is applied 
systemically. Therefore, non-specific targeting of cells 
leads to many unwanted and sometimes severe side 
effects. Magnetic particles are engineered with a chem-
otherapeutic agent and designed to be target specific, 
reaching the area of the tumor cell with the help of a 
magnet (Fig.  2). Functionalized MNPs are internalized 
through caveolae structures or by endocytosis, a pro-
cess, which is facilitated by specific receptors, [48]. Once 
in the cytoplasm, the drug is released performing the 
desired action in the target cells. Ideally, MNPs are then 
subsequently biodegraded [49]. To enhance the ability of 
MNPs to reach the targeted tumor cells, MNPs are often 
functionalized with antibodies in addition to their trans-
porting drug. These antibodies support targeting of the 
tumor cell by specific binding and allowing for a precise 
treatment of the targeted tissue [50–52].
Similar to the loading of MNPs with chemotherapeu-
tics, MNPs can be equipped with radioactive isotopes 
or radionuclides. The radionuclide-loaded MNPs are 
guided to the tumor cells and, upon internalization, kill 
then cancer cells through continuous irradiation [53–55]. 
Half-life times of the used radioactive isotopes have to be 
considered for the treatment to allow for efficient tumor 
cell killing, but at the same time not damaging normal 
tissue once the cancer cells have been eliminated.
Genetic disease treatment presents a further pos-
sible field of application for magnetic nanosensors. 
Classically, patients with a genetic disease, are treated 
with exogenous DNA to correct mutations, which are 
responsible for the disease. Also, antisense-RNA can 
be used to silence defective genes. However, with the 
Fig. 1 General synthesis procedure to fabricate a magnetic 
nanosensor from a magnetic nanoparticle. Production of the 
magnetic particle core entails providing the magnetic material and 
protecting it against dissolution or changes. Core shell geometries 
with silica, polymer or carbon coatings are the most frequently 
applied layers connecting the magnetic core with the biochemical 
functionality. After application of a linker, a specificity creating moiety 
must be attached. Suitable entities are antibodies, nucleic acids and 
other biomolecules
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current treatment methods different challenges are 
faced: (1) There is a clear lack of tissue specificity. (2) 
Transfection efficiency needs to be improved as intro-
duction of the nucleic acids into cells is difficult using 
classical approaches [56]. (3) The life time of the DNA 
is very limited since it degrades fast. Therefore, MNPs 
may pose as a possible efficient transport system for 
gene therapy. The ability to target specific tissue and 
increasing transfection efficiency would overall aug-
ment gene transfer [57].
Contrast agent carrier
Another group of MNPs are magnetic nanosensors 
used as contrast agents in MRI to image specific organs. 
After injection, the magnetic nanosensors agglomer-
ate in specific areas and—upon irradiation with radio 
waves—enhance the contrast and therefore increase 
image quality [58]. Such contrast agents are delivered as 
SPIONs, coated with hydrophilic polymers for stabiliza-
tion in solution. Some SPION-based contrast agents are 
clinically approved and in use for liver, bowel and vascu-
lature imaging [11, 59].
Hyperthermia
Similar to the use of functionalized MNPs as contrast 
agents is the technique of hyperthermia. A rise in 
tumor temperature makes cancer cells more susceptible 
to chemotherapy or radiation, and can directly cause 
cellular death. Therefore, MNPs as energy-transducing 
particles may be used locally to overheat tumor cells. 
This would be an attractive method for treatment of 
deep tissue seated tumors [60, 61].
Magnetic nanosensors as elimination system
Blood purification describes the second category where 
magnetic nanosensors may be applied clinically, focus-
ing on removal of non-cellular and cellular compounds. 
The challenge for magnetic nanosensors in blood puri-
fication lies in the functionalization of the MNPs with 
a suitable linking agent such as a metal coordinative 
ligand, a peptide or an antibody to bind solely the spe-
cific target [12, 62].
Fig. 2 Magnetic nanosensors loaded with a chemotherapeutic to be injected intravenously and directed with a magnet towards the tumor tissue. 
In this specific example, the particle bound chemotherapeutic drug is introduced in the blood stream to treat a liver tumor. Preferred deposition of 
the drug in the liver through application of a local magnet improves the concentration of drug in the target organ and is expected to reduce side 
effects as less of the toxic drug reaches other organs
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Removal of both low‑ and high‑molecular weight blood 
compounds
While current methods such as adsorption, filtration or 
dialysis clearly allow elimination of small molecules (i.e. 
potassium, urea, creatinine), harmful substances are 
often biomolecules of large size (i.e. antibodies, endo-
toxins, etc.). To remove complex-structured compounds, 
plasma exchange is mandatory with the disadvantage of 
loss of plasma [63]. As an alternative, filtration through 
antibody-coated columns is an option, but the nature of 
the compound has to be known with an according anti-
body being available [64]. Therefore, magnetic nanosen-
sors are an interesting approach to reliably eliminate all 
kind of different compounds from the blood in an extra-
corporeal device approach (basic principle described in 
Fig.  3) (extracorporeal purification system described in 
Fig. 4).
Iron carbide nanoparticles have been functionalized 
in diverse ways to purify blood from metal ions, steroid 
drugs (i.e. digoxin known as an antiarrhythmic agent) 
as well as proteins (i.e. interleukins, IL, as inflammatory 
mediators). Successful elimination of lead, digoxin and 
IL-6 was achieved with an EDTA-like chelator as metal 
coordinating ligand, with an antibody such as digoxin-
binding FAB fragments or with an anti-IL-6 antibody, 
respectively [65]. With the help of an extracorporeal 
blood purification system, these in  vitro results were 
successfully reproduced in  vivo in rats [66]. Particularly 
digoxin data were intriguing as they clearly showed a 
lowering of digoxin concentrations from a toxic to a ther-
apeutic blood level within a short time.
When considering clinical scenarios, which would 
profit from blood purification using magnetic nanosen-
sors, sepsis may be a main focus. Sepsis is a complex 
overwhelming response of the body to a systemic infec-
tion. It is potentially life-threatening as it often leads 
to organ failure and finally to death [67]. On one hand, 
the presence of extensively produced inflammatory 
mediators such as cytokines or complement products 
could be decreased in an extracorporeal blood purifica-
tion approach with the help of magnetic nanosensors. 
It has been hypothesized that the removal of such enti-
ties would be highly beneficial [68] (Fig. 4). On the other 
hand, also toxins could be eliminated. Polymyxin B, an 
antibiotic, which binds and inactivates endotoxins, was 
used to functionalize magnetic nanoparticles. In a first 
Fig. 3 In an ex vivo approach the injected nanosensors are derivatized as to catch a contaminant of interest after mixing. Beside elimination of 
contaminants, a magnetic separation step also allows recollecting the injected agents, and separately removing the caught contaminants from 
the carrier, followed by an analysis of the desorbed contaminants. The possibility to sample contaminants in larger blood volumes but desorb 
the collected material into a small volume further permits up‑concentration thus facilitating the detection of low concentration contaminants or 
biomarkers
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approach, human blood contaminated with endotoxin, 
was successfully purified with these polymyxin B-coated 
MNPs (Fig.  3) [69]. Recently, SPIONs have been func-
tionalized with peptides from binding motives of agglu-
tinating salivary proteins acting as specific pathogen 
scavengers. These functionalized SPIONs were then 
utilized to bind endotoxin [70]. In another approach, 
the capturing of lipopolysaccharides (endotoxins) with 
functionalized MNPs was studied. The authors pro-
duced particles composed of iron oxide nanoparticles 
and macrophage membranes to capture lipopolysaccha-
rides in vivo in rats [71]. These nanoparticles significantly 
attenuated systemic inflammation. At the same time, 
mortality of endotoxemic rats was decreased.
Removal of blood cells
Another area of interest in blood purification is the 
identification and/or removal of blood cells. This gives 
rise to the possibility of fast and efficient detection and 
treatment of diseases. A classical way of  cell separa-
tion is based on cell size with the disadvantage, how-
ever, of not being able to separate cells of similar sizes. 
Also, when using the affinity cell separation technique, 
chemical or electrical properties may be similar in dif-
ferent cells. Magnetic separation based on the use of 
nanoparticles suffers from no such limitation as MNPs 
are coated with specific antibodies directed against a 
surface marker of the desired cells [72].
Isolation of hematopoietic stem cells from bone mar-
row or peripheral blood from a healthy donor presents 
a realistic future application for MNPs. Such donor 
cells are used to reintroduce functional stem cells in 
a recipient after chemotherapy for leukemia or lym-
phoma with killing of not only neoplastic, but also of 
growing cells by the cytotoxic agents. Although due to 
the low abundance of stem cells in bone marrow aspi-
rate or peripheral blood, it is challenging to separate 
them, the use of magnetic nanosensors may present a 
suitable approach [73].
Another application for the removal of cells may 
be explored targeting circulating tumor cells (CTCs). 
These cells are thought to be a key factor in the process 
of metastasis [74]. Their presence in the blood indicates 
poor outcome [75, 76]. Elimination of CTCs via hemodi-
alysis might enforce the suppression of further metasta-
sis, thereby improving outcome.
Fig. 4 The therapeutic use of magnetic nanoparticles to remove significant parts of a blood contaminant requires injection and mixing of the 
magnetic particles during a prolonged time. After binding, the injected agent has to be removed in a magnetic separation step and ideally 
guarantees that essentially no particles are fed back into the patient’s body. In a typical clinical setup, a diagnostic step with detection of specific 
targets is expected to then lead to the treatment step using an adapted mix of magnetic agents
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Important to note when targeting blood purification 
with magnetic nanosensors is the need for a suitable 
device, which allows for efficient injection, mixing and 
removal of the magnetic nanosensors [77–81] (Fig. 4).
Requirements for specific applications using magnetic 
nanosensors
Among magnetic nanosensors certain characteristics 
are shared for in  vivo as well as extracorporeal appli-
cations. First and foremost, the particles need to be 
biocompatible. Therefore, they should refrain from 
non-specific adsorption as well as from agglomera-
tion (unless desired in the target tissue). Second, it is 
a prerequisite that the particles are non-toxic. Not 
only cytotoxicity, but also tissue inflammation should 
be avoided. These are key parameters for the safe use 
of nanosensors, which are discussed later in the risk 
assessment part. Even magnetic nanosensors are used 
in a similar way in  vivo and extracorporeally, differ-
ent requirements need to be met for each application. 
Generally, the particles used for in  vivo applications 
are smaller to account for faster transport and tissue 
penetration inside the body in comparison to extracor-
poreal separation applications. Additionally, for in vivo 
applications the nanoparticles need to be either small 
enough to be filtered by kidneys or big enough to be 
eliminated by liver and spleen or they are biodegrada-
ble. All these characteristics decrease the risk for accu-
mulation in the body.
Specific requirements for the synthesis of magnetic 
nanosensors depending on the purpose of the applica-
tion are summarized in Table 1. Blood purification was 
taken as a single application since the requirements 
needed are similar for separation of small moieties as 
well as cells.
Risk assessment of MNPs for clinical applications
When considering in vivo as well as extracorporeal MNP 
applications safety aspects are of utmost importance. In 
general, since the discovery of the nanoscale, nanoparti-
cles opened up new fields of research and subsequently 
various applications of nanoparticles were found. Due to 
their small size, nanoparticles were initially believed to 
have little to no influence on living organisms. Only later, 
when researchers started broader investigations regard-
ing possible risks of nanoparticles, adverse effects were 
discovered.
In vitro assessment of nanoparticles concerning toxic-
ity is undertaken in the same way as the assessment of 
chemical compounds in solution [91]. This is problem-
atic due to the fact, that nanoparticles do not have the 
same properties as chemical compounds in solution with 
a possible different behaviour. Therefore, it is important 
to formulate protocols tailored to the risk assessment 
of nanoparticles including all possible aspects of harm 
MNPs could present with [92]. Over the last few years the 
Center for Drug Evaluation and Research within the FDA 
has supported and performed many studies concerning 
the regulatory aspect in risk assessment of drug-contain-
ing nanomaterials [93]. Generally, evaluations of such 
nanomaterials are performed on a case-to-case basis, 
and protocols are then established and implemented for 
the risk evaluation of nanoparticles in a more universal 
way. This clearly poses a challenge as the variety of nano-
particles produced is ever expanding and new possible 
nanoparticles with different shapes, compositions and 
surface functionalizations are produced with unforesee-
able effects towards organisms.
Various studies exist assessing possible toxic effects 
of MNPs in a living organism. Surface characteris-
tics determine distribution within the body, whereas 
size, dose and entry point of nanoparticles are impor-
tant as well. In general, inflammation may be triggered 
Table 1 Requirements for in vivo and extracorporeal applications using magnetic nanosensors
Application Requirements References
Drug delivery Stability of drug‑nanoparticle composite to guarantee no premature release
Composite optimally entirely biodegradable
High magnetization for precise and efficient magnetic transport
[8, 82]
Contrast agents High magnetization desired to achieve good contrast
Ability to strongly shorten relaxation times in tissue
[83, 84]
Hyperthermia Specificity needed towards target tissue and ability to penetrate cells
Magnetic anisotropy (shape, crystallinity, surface properties) and size/size‑distribution influence 
heating efficiency
15–20 nm core size optimal with low dispersity to achieve high heating efficiency
[61, 85–87]
Blood purification Good dispersions for optimal binding speed to target
High magnetization or larger particles (for SPIONs) for a later efficient separation
Stable coating, non‑interactive with other blood species
High specificity needed for removal of non‑abundant moieties (e.g. CTC)
[88–90]
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through stimulation of effector cells, producing proin-
flammatory mediators, whereas the proinflammatory 
effect seems to be surface-dependant [94]. When MNPs 
remain in the tissue over time, chronic inflammation 
may be another consequence leading to fibrosis of the 
affected organ [95, 96]. Finally, MNPs may evoke dam-
age, which triggers the development of cancer [97]. This 
is of particular concern as long-term studies are still 
missing.
Nanoparticles, once present in the body, may target 
various systems. There are effects of nanoparticles found 
on the circulatory system, where nanoparticles indirectly 
influence for example blood pressure [98]. Important 
to note when looking at the circulatory system is the 
fact that nanoparticles are engineered to influence the 
coagulation system of the blood [99]. At the same time, 
MNPs, designed for any other indication, may evoke an 
unwanted pro- or anticoagulant effect in the blood [100].
A recent study mimicked the clinical scenario with fer-
romagnetic iron carbide nanoparticles used for blood 
purification methods, which theoretically escaped mag-
netic separation and entered the blood system of mice 
[101]. These particles mainly accumulated in the lungs, 
liver and spleen [101]. Although, MNPs were still present 
in the organs after a year, they were well tolerated and no 
significant immunological response was detected over 
time [101].
The reproductive system is another target of nanoparti-
cles with possible detrimental effects. Upon in vivo appli-
cations, nanoparticles may accumulate in reproductive 
organs [102, 103], where they have direct effects on germ 
cells with reduced cell count or activity in both, female 
and male germ cells [104, 105]. Furthermore, nanopar-
ticles are able to alter or damage DNA in cells, which 
would be especially problematic in germ cells [106]. In a 
recent in vitro study, uptake of coated SPIONs in granu-
losa cells was tested. It was found that depending on the 
coating, no or only low uptake and toxicity of SPIONs 
was observed [107].
All these various possible effects that certain nanopar-
ticles may or may not exhibit display the challenge in the 
risk assessment for nanoparticles in medical applications. 
Regulatory and toxicology studies have to address the 
fate of such nanosensors. Therefore, available magnetic 
nanomaterials for in  vivo applications become limited. 
Up to now only SPIONs, due to the biodegradability of 
iron oxide, are clinically used. Non-biodegradable MNPs, 
even though they may be biocompatible, pose a challenge 
as accumulation and therefore unknown and detrimen-
tal effects in tissue are possible. Mechanisms are needed, 
which allow total excretion of such non-biodegradable 
MNPs. To the best of our knowledge, this is so far not 
achieved.
In nanosensor systems where the particles elimi-
nate compounds from the blood, ideally all MNPs are 
removed from the blood with a strong magnet before the 
blood is redirected into the body. Therefore, biodegrada-
bility and excretion is not a relevant aspect. This alters 
the question relevance for regulatory approval. Never-
theless, biocompatibility in blood, dispersability and the 
subsequent removal of the magnetic nanosensors are 
to be considered. Reintroduction of the blood has to be 
performed excluding even traces of nanosensors. Else-
wise, they will be introduced into the bloodstream of the 
patient and this may have harmful consequences [108].
Recently, a method for detection of trace amounts of 
MNPs in complex fluids was published [89]. The authors 
used a magnetometric sensor, which detects low mag-
netic fluctuations to determine the presence of iron and 
cobalt MNPs under flowing conditions. The advantage of 
this method is not only the very low detection limit, but 
also the sample is not destroyed during analysis, which 
enables on-line detection. It is believed that this method 
may be used in combination with a blood purification 
device to reliably proof that no particles are introduced 
into the patient. Additionally, when combining this 
method with protocols for safe handling of MNPs, the 
acceptance of using MNPs for blood purification may be 
further strengthened.
Future perspectives
The use of magnetic nanosensors in clinical applications 
has seen great advances over the last few years. Magnetic 
nanosensors for MRI are readily used as contrast agents 
in clinical applications [6, 59]. Additionally, with the pos-
sibility to combine diagnostics and simultaneous ther-
apy, so called theranostics, a new class of functionalized 
MNPs may be used in the future for clinical applications 
[109, 110]. Concerning gene therapy, the main challenge 
still lies in the production or functionalization of suitable 
MNPs and risk assessment thereof.
In extracorporeal applications for magnetic nanosen-
sors decent progress has been made. With  CliniMACS®, 
a method to separate T-Cells from blood, a first FDA-
approved clinical application for magnetic nanosensors 
has been established [111].
When looking towards the treatment of sepsis, a lot 
of research for the application of magnetic nanosen-
sors is currently ongoing, academic and industrial wise 
[112]. Several improvements still have to be done. At 
one point, the device for the removal of MNPs should 
match the required flow rates and separation efficien-
cies in order to avoid any magnetic nanosensors to be 
directed into the blood stream. Concerning the func-
tionalization of the magnetic nanosensors to apply in 
blood purification to treat sepsis, particles have to be 
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developed, which remove a wide range of sepsis caus-
ing pathogens and additionally remain inert to any 
other cell or molecular entities in blood. This could be 
bypassed by creating mixtures of different magnetic 
nanosensors, each one with a binding site functional-
ized to remove a specific sepsis-causing pathogen or 
to eliminate an inflammatory mediator or complement 
products.
Even though the progress in possible clinical applica-
tions is visible, risk considerations may not be left out. 
A magnetic nanosensor needs to be safe for handling 
and treatment. There are still possible unclear variables 
towards the safety of magnetic nanosensors. Not to forget 
is the fact that long-term studies with magnetic nanosen-
sors are not yet available to address and define possible 
long-term effects of such nanoparticles.
To sum up, magnetic nanosensors towards medical 
applications, show great promise as novel medication-, 
diagnostic- and separation tools. The variety of already 
approved magnetic nanosensors as contrast agents in 
MRI boost the confidence that magnetic nanosensors 
may also be reliably applied in  vivo for targeted drug 
delivery. For extracorporeal applications, the treatment 
of sepsis with magnetic nanosensors shows great promise 
should it become commercially available.
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